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OBJECTIVES We studied the incidence of myocardial injury in aneurysmal subarachnoid hemorrhage
(SAH) using the more sensitive cardiac troponin I (cTnI) assay, correlated changes in cTnI
with creatine kinase, MB fraction (CK-MB), myoglobin, and catecholamine metabolite
assays, and examined the predictive value of changes in cTnI for myocardial dysfunction.
BACKGROUND Myocardial injury in aneurysmal SAH as evidenced by elevated CK-MB fraction has been
reported. Little published data exist on the value of cTnI measurements in aneurysmal SAH.
METHODS Thirty-nine patients were studied for seven days. Clinical cardiovascular assessment,
electrocardiographic (ECG), echocardiography, cTnI, CK, CK-MB and CK-MB index,
myoglobin and 24-h urinary catecholamine assays were performed in all patients. The ECG
abnormalities were defined by the presence of ST-T changes, prolonged QT intervals, and
arrhythmias. An abnormal echocardiogram was defined by the presence of wall-motion
abnormalities and a reduced ejection fraction. The severity of SAH was graded clinically and
radiologically.
RESULTS Eight patients demonstrated elevations in cTnI (upper limit of normal is 0.1 mg/liter with the
immunoenzymatic assay and 0.4 mg/liter with the sandwich immunoassay), while five had
abnormal CK-MB levels (upper limit of normal is 8 mg/liter). Patients with more severe
grades of SAH were more likely to develop a cTnI leak (p , 0.05). Patients with cTnI
elevations were more likely to demonstrate ECG abnormalities (p , 0.01) and manifest
clinical myocardial dysfunction (p , 0.01) as evidenced by the presence of a gallop rhythm
on auscultation and clinical or radiological evidence of pulmonary edema as compared to
those with CK-MB elevations. The sensitivity and specificity of cTnI to predict myocardial
dysfunction were 100% and 91%, respectively, whereas the corresponding figures for CK-MB
were 60% and 94%, respectively. Elevations in myoglobin levels (upper limit of normal ,70
mg/liter) and urinary catecholamine metabolites (urinary vanilmandelate/creatinine ratio
upper limit of normal, 2.6) are a nonspecific finding.
CONCLUSIONS Measurements of cTnI reveal a higher incidence of myocardial injury than predicted by
CK-MB in aneurysmal SAH, and elevations of cTnI are associated with a higher incidence
of myocardial dysfunction. Thus, cTnI is a highly sensitive and specific indicator of
myocardial dysfunction in aneurysmal SAH. (J Am Coll Cardiol 2000;36:1328–35) © 2000
by the American College of Cardiology
Aneurysmal subarachnoid hemorrhage (SAH) has an esti-
mated incidence of 6 to 7.5 cases per 100,000 persons per
annum (1) and accounts for 6% to 10% of all strokes and
22% to 25% of cerebrovascular deaths. Cardiac abnormali-
ties, as evidenced by release of cardiac enzymes, changes in
electrocardiography (ECG) or clinical or echocardiographic
evidence of left ventricular dysfunction, occurring in asso-
ciation with aneurysmal SAH, have been well described
(2–5).
The etiology of the myocardial changes remains largely
speculative. While the temporal profile and pattern of ECG
changes suggest that myocardial ischemia may be contrib-
utory, regional myocardial dysfunction in association with
ST segment elevation has been described in patients on
whom subsequent coronary angiography showed no ob-
structive lesions (6). The weight of evidence points to a
catecholamine-mediated damage based on histological le-
sions in the myocardium that resemble those of a catechol-
amine myocarditis (7,8) and the presence of elevated levels
of catecholamines in the serum (9,10). It is possible that
these patients are exposed to a catecholamine surge at the
time of the bleed or subsequently during the course of the
illness.
Despite a large body of evidence testifying to the devel-
opment of myocardial injury in SAH (6,11–13), the true
incidence in this population remains unknown. The ECG
changes are often nonspecific and transitory (2). Several
studies have examined cardiac enzyme release (typically
creatine kinase, MB fraction, CK-MB), but interpretation
can be difficult as CK-MB may be released from noncardiac
muscle damage (14,15). Furthermore, some patients may
develop clinically important myocardial dysfunction due to
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sublethal injury that does not result in CK-MB release (16).
Echocardiography may detect left ventricular systolic dys-
function due either to transitory metabolic abnormalities or
permanent ischemic damage.
In recent years, considerable investigative interest has
been directed at the cardiac troponin I (cTnI), a new marker
of myocardial injury. Cardiac troponin I is a regulatory
protein highly specific for the cardiac muscle (17). Small
amounts of cTnI may be released from a cytosolic pool due
to sublethal myocyte injury, but larger amounts of cTnI
release imply irreversible cell death and breakdown of the
contractile apparatus. Troponin release is also accepted as
the most specific marker of myocardial necrosis in patients
with myocardial infarction (14). The major advantage of
cTnI is its ability to detect myocardial cell damage that is
undetectable by conventional enzyme methods, with high
sensitivity and specificity (18). Although a number of
studies demonstrate the greater specificity and sensitivity of
cTnI as compared to CK-MB for the detection of myocar-
dial damage from various etiologies (14,16,19,20), there is
little published data with regard to cardiac troponins in
patients with subarachnoid hemorrhage.
The aims of this study were:
1. to define the incidence of cardiac injury in patients with
aneurysmal SAH as determined by cTnI release;
2. to compare the predictive value of elevations in cTnI,
CK-MB mass and serum myoglobin in predicting myo-
cardial injury in these patients; and
3. to investigate the relationship between urine catechol-
amine metabolite levels and cTnI and between elevated
cTnI and neurological complications.
METHODS
The study was approved by the Royal Brisbane Hospital
Research Ethics Committee. Informed consent was ob-
tained from patients or the next of kin depending on the
conscious state of the patient at the time of enrollment. The
study period extended from April 1998 to April 1999.
Inclusion criteria. All patients with spontaneous, nontrau-
matic acute SAH confirmed on computed tomographic
(CT) scan of the brain and presenting within 24 h of onset
of symptoms were eligible for inclusion in the study.
Exclusions. Patients with a history of myocardial infarc-
tion, cardiac surgery, or trauma within the previous three
months, cardiomyopathy and renal impairment defined as
serum creatinine more than 0.12 mmol/liter were excluded
from the study.
Following enrollment, the severity of subarachnoid hem-
orrhage (SAH) was graded clinically using the Hunt and
Hess classification (21). Patients with grade I SAH were
admitted to the neurosurgical ward, whereas those with
grades II through V were managed in the neurosurgical
intensive care unit (ICU). All patients in the ICU had
continuous ECG monitoring and arterial cannulation for
invasive pressure monitoring as part of standard clinical
practice. When patients required sedation for intensive care
procedures, facilitation of positive pressure ventilation or
transport, propofol (1–3 mg/kg/hour) in combination with
alfentanil (10–20 mg/kg/hour) or midazolam (0.1–0.2 mg/
kg/hour) in combination with fentanyl (1–2 mg/kg/hour)
were used.
Endotracheal intubation was performed and positive
pressure ventilation initiated when clinically indicated.
Four-vessel cerebral angiography was performed within
48 h of admission to the hospital to identify the location of
the aneurysm. In all patients, intravenous (IV) nimodipine
infusion was commenced at an initial infusion rate of 5
mg/kg/hour, which was progressively increased over a 5-h
period to a maximum dose of 30 mg/kg/hour. All patients
were then maintained on this dose for a week unless the
presence of side effects such as hypotension dictated a
reduction in the dose of, or total cessation of, nimodipine.
Patients were monitored for evidence of vasospasm using
daily Doppler flow measurements and, in select cases,
cerebral angiography.
Clinical assessment. Patients were examined daily for
evidence of cardiac dysfunction as evidenced by the presence
of a gallop rhythm on auscultation and clinical or radiolog-
ical evidence of pulmonary edema. Both the need for and
the timing of commencement of inotropic and/or pressor
therapy were recorded.
Biochemical measurements. Measurements of CK, CK-
MB, CKMB index, and cTnI were performed daily for
seven days on all patients. For estimation of CK, CK-MB
and cTnI blood samples were collected in plasma separator
tubes. Total CK activity (upper reference limit 210 U/liter,
lower limit of detection 35, CV 3%) was measured on a
Hitachi 747 analyzer. The CK-MB mass (upper reference
limit of normal 8 mg/liter, lower limit of detection 0.1
mg/liter, CV 6.4%) was measured on the Beckman Access
analyzer. In the first 29 patients, the serum cTnI levels were
measured by an immunoenzymatic assay (reference range
for upper limit of normal 0.1 mg/liter, lower limit of
detection 0.01 mg/liter, CV 25%) using the Access analyzer.
Owing to potential interference with this assay by mouse
antibodies, an antibody test was performed in all patients
with elevated troponin by this assay to exclude false positive
rise in cTnI due to mouse heterophile antibodies. From
December 1998, the method of assaying cTnI was changed
to a sandwich immunoassay (reference range for upper limit
of normal 0.4 mg/liter, lower limit of detection 0.2 mg/liter,
Abbreviations and Acronyms
cTnI 5 cardiac troponin I
CK-MB 5 creatine kinase MB fraction
EF 5 Ejection fraction
PaCO2 5 Partial pressure of arterial carbon dioxide
SAH 5 subarachnoid hemorrhage
VMA 5 vanilmandelate
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CV 10%), which incorporated two monoclonal antibodies
specific for two different epitopes of cTnI. There is no
reported interference with this assay by heterophile anti-
mouse antibodies. The cTnI levels in the last 12 patients
were measured using the new assay.
Because of the change of the troponin assay after patient
number 29, a methods comparison was performed between
the old and the new technique on blood samples (not
belonging to the study) submitted to the laboratory for
troponin analysis. Sixty-seven plasma samples from patients
were analyzed by both methods. Samples that were positive
by the immunoenzymatic assay (older method) were diluted
with mouse serum to exclude heterophile interference, and
if the samples were found to be positive on the reassay, they
were excluded from comparison. Positive interference was
found in nine samples that were reassayed. The data
revealed a strong correlation (r2 5 0.8) between the two
methods.
Serum myoglobin and urinary vanilmandelate (VMA)
were measured in the first 30 patients enrolled into the
study. Serum myoglobin levels were measured every 6 h for
the first 24 h of admission using latex-enhanced nephelom-
etry (reference range for upper limit of normal 70 mg/liter,
lower limit of detection 6.8 mg/liter, CV 9%) on a BN2
Analyzer. In addition, in the first 30 patients, urinary levels
of VMA (reference range for upper limit of normal 25
mmol/liter, lower limit of detection 1 mmol/liter, CV 5%)
were performed daily for three days using high-performance
liquid chromatography.
ECG and echocardiography. Twelve-lead ECG with
consistent chest leads positioning was performed daily for
seven days. The ECGs were considered abnormal if the T
wave was inverted or flattened, the S-T segment was
elevated or depressed, the QT interval was prolonged, or if
an arrhythmia was present (22). Echocardiography was
performed within 24 h of symptom onset by a cardiologist
blinded to the results of the cardiac clinical examination,
ECG analyses, radiographic data and cardiac enzyme anal-
ysis. Transthoracic studies (TTE) were performed unless
the patient was intubated and ventilated, in which case a
transesophageal (TEE) study was undertaken. The echocar-
diograms were performed on Hewlett-Packard SONOS
1500 or 5000 machines, with multiplane imaging for the
transesophageal studies. Ejection fraction (EF) was calcu-
lated by conventional algorithms from either parasternal
M-mode measurements or the area-length method from the
transthoracic apical two- and four-chamber views or the
corresponding views from the transesophageal window.
Using standard tomographic planes, the left ventricle was
divided into 16 wall segments as defined by the American
Society of Echocardiography (23). Wall motion was classi-
fied as normal, hypokinetic, akinetic, or dyskinetic in each of
the myocardial segments. An echocardiogram was reported
as abnormal if there was evidence of wall-motion abnormal-
ities or a globally reduced EF (,50%) (24,25).
Neurological assessment. At the end of the study, radio-
logical grading of the severity of SAH was performed
according to the Fisher scale (26) by a consultant radiologist
who was blinded to the clinical and biochemical data.
Statistical analysis. Categorical variables were compared
by the chi-square test, or the Fisher exact test for compar-
isons involving small cell sizes. Continuous variables were
compared by linear regression analysis. An alpha value of
0.05 was accepted as the boundary for rejection of the null
hypothesis. Alpha values were not adjusted for multiple
comparisons. A p , 0.05 was taken as statistically signifi-
cant.
RESULTS
Demographic and clinical data. Forty-one patients were
enrolled into the trial, of whom 39 were considered suitable
for analysis. Two patients had fewer than 24 h of data
collection and did not have the full set of ECG, biochem-
ical, and echocardiographic investigations. One of these
patients died within 24 h of enrollment, and the other
patient withdrew from the study in the first 24 h. The
clinical characteristics of the study population are illustrated
in Table 1.
Cardiac enzyme levels. Eight of the 39 patients demon-
strated elevations of cTnI (20%). Five of the eight patients
with elevated cTnI also had an elevated CK-MB, whereas
no patient with a normal cTnI had elevation of CK-MB.
The peak elevation in cTnI levels was seen on day 1 in six
patients and on day 2 in two patients. The enzymatic and
echocardiographic data of those patients who demonstrated
elevated serum troponins are listed in Table 2. Serum
myoglobin was elevated in 11 of the 30 patients in whom it
was measured. Myoglobin release was not correlated with
cTnI or CK-MB release.
Relation between urinary catecholamine release and en-
zyme abnormalities. Twenty-six of the 30 patients (87%)
demonstrated elevated urinary VMA levels. Urinary VMA
level was found to be highly sensitive (100%), but a
nonspecific (17%) predictor of elevations in serum cTnI.
Table 1. Clinical Characteristics of the Study Patients
Total number of patients 39
Gender distribution M 15, F 24
Mean age in years (range) 54 (31–78)
Grade of SAH (Hunt and Hess)
1 13
2 12
3 6
4 3
5 5
Median Glasgow Coma score 13
Median Fisher scale score 4
Mean heart rate 90 6 39
Mean arterial pressure in mm Hg 94 6 29
Arterial oxygen saturation (%) 96 6 4
PaCO2 (torr) 37 6 8
Number of survivors 34
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Echocardiographic findings. Twelve patients underwent
transesophageal echocardiography; 27 patients were inves-
tigated with a transthoracic echocardiogram. Five patients
(13%) had abnormal echocardiograms. Five of the eight
patients in the elevated cTnI group had impaired myocar-
dial contractility on echocardiography (p , 0.0001). The
sensitivity and specificity of cTnI to predict myocardial
dysfunction as defined by echocardiography were 100% and
91%, respectively. Three of the 5 patients with elevated
CK-MB and 2 of the 34 patients with normal CK-MB also
had abnormal echocardiograms (CK-MB sensitivity 60%,
specificity 94%). Only one of the 11 patients with abnormal
myoglobin group demonstrated impaired myocardial con-
tractility (p 5 NS). The mean EF of those patients with
elevated troponin was 53% as compared to 72% with normal
troponin (p 5 0.02), whereas no significant differences were
noted in the mean EF between patients with elevated
CK-MB and normal CK-MB levels. The individual EF
data for the cTnI and the CK-MB groups are illustrated in
Figures 1 and 2.
Electrocardiographic abnormalities. Abnormal ECGs
were detected in 23 (59%) patients. Twenty-five ECG
abnormalities were detected in the 23 patients. The ST-T
changes (17/39) were the most frequent, followed by pro-
longed QT intervals (6/39) and supraventricular arrhyth-
mias (4/39). The ST-T abnormalities were observed mainly
in the inferolateral leads (11/39). Patients with elevated
troponin had a statistically higher proportion of ST-T
changes (39%, p , 0.01) as compared to those with elevated
CK-MB (22%, p 5 0.1).
Figure 1. Individual echocardiographic data of patients with normal and
abnormal cTnI.
Figure 2. Individual echocardiographic data of patients with normal and
abnormal CK-MB.
Table 2. Enzymatic and Echocardiographic Data of Patients With Elevated Troponin
Patient
No.
Peak
Troponin
Levels ECG Findings EF
Other Findings on
Echocardiography
Clinical or
Radiological
Myocardial
Dysfunction
3 0.15† Normal 84 Normal contractility Absent
6 0.27 T-wave inversion
inferior leads
25 Global reduction in LV contractility Present
9 0.11 T-wave inversion
anterior leads
40 RWMA of inferior, lateral and
anterior wall
Absent
12 0.17 Global ST
depression
69 Normal contractility Present
14 0.19† Prolonged QT,
lateral wall ST-T
changes
50 Circumferential hypokinesia at basal
level and severe hypokinesia of
anterior wall and septum at mid-
cavity level
Present
19 0.78† Prolonged QT,
lateral wall ST-T
changes
64 Normal contractility Absent
30 1.54*† T-wave inversion
inferior leads
35 Global hypokinesia Present
33 3.1*† Global ST
depression
50 Severe septal hypokinesia and
moderate hypokinesia of the
infero-apical segment
Absent
*cTnI assay in these patients was performed by the sandwich immunoassay using monoclonal antibodies (upper limit of normal 0.4 mcg/ml). †These patients also demonstrated
an increase in CK-MB levels.
RWMA 5 regional wall motion abnormality.
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Clinical outcomes. Six patients developed clinical signs of
myocardial dysfunction based on clinical and radiological
criteria. One patient required inotropic therapy with epi-
nephrine to improve myocardial function and gas exchange.
Four of the eight patients with raised troponin level devel-
oped clinical signs of myocardial dysfunction compared to
two patients of those with normal troponin level (p , 0.01).
Only 2 of the 5 patients with raised CK-MB developed
clinical myocardial dysfunction, as compared to 3 of the 34
with normal CK-MB (p 5 NS). The cardiovascular data of
both the cTnI and the CK-MB groups are summarized in
Figure 3.
Relationship between clinical grade of SAH and bio-
chemical abnormalities. Twenty-six of the 39 patients
were categorized as grades 1–2 at the time of presentation;
the remaining 13 were grouped as grades 3–5. The more
severe grades of SAH (grades 3–5) were associated with a
greater incidence of raised troponins (46%) (p , 0.005) and
CK-MB (30%) (p , 0.05) values. Patients with less severe
grades of SAH (grades 1–2) demonstrated a smaller inci-
dence of both troponin (8%, p , 0.005) and CK-MB
elevation (4%, p , 0.05).
Relationship between radiological grade of SAH and
biochemical abnormalities. The brain CT scans of 37
patients were analyzed retrospectively for the radiological
grade of SAH based on the Fisher score (scans of two
patients were not available for analysis). All 7 patients who
were grade 4 on the Fisher scale demonstrated an elevated
cTnI as compared to the 30 patients who were grades 1–3
(p 5 0.04). No statistically significant relationship was
demonstrable between the radiological grading of SAH and
CK-MB mass (p 5 0.08), although the study was under-
powered to exclude this relationship.
Relationship between biochemical abnormalities and the
development of cerebral vasospasm. In all, 16 of the 39
patients (41%) demonstrated evidence of vasospasm, based
on clinical examination, transcranial Doppler ultrasonogra-
phy, and cerebral angiography. All five patients with a raised
CK-MB mass demonstrated evidence of vasospasm (p ,
0.05), whereas five of the eight patients with elevated
troponin levels demonstrated vasospasm (p 5 NS). The
relationship between biochemical changes and cardiac and
neurological outcomes are shown in Tables 3 and 4.
DISCUSSION
The primary findings of this study are that cTnI is elevated
in 20% of patients with SAH and that these patients are
more likely to manifest echocardiographic and clinical
evidence of left ventricular dysfunction. Patients with more
severe grades of SAH were more likely to develop an
elevated level of serum cTnI. Although five of the eight
patients with elevated cTnI also had elevated CK-MB,
cTnI was a more sensitive and specific indicator of left
ventricular dysfunction assessed clinically or by echocardi-
ography. However, there was no relationship between a
raised cTnI and cerebral vasospasm.
Comparison with published literature. The CK-MB rise
observed in this study is in keeping with the data of Rudehill
et al. (2) and Mayer et al. (27). The lack of a significant
relationship between elevations in myoglobin and cTnI are
also in line with published data (28,29). The demonstration
of a significant relationship between elevations in cTnI and
myocardial dysfunction in SAH provides further evidence of
the usefulness of cTnI as a marker of myocardial damage,
irrespective of the etiology. The lack of correlation between
the serum levels of other markers and myocardial dysfunc-
Figure 3. Cardiovascular data of both the cTnI and the CK-MB groups.
Solid bar 5 raised cTnI; open bars 5 raised CK-MB.
Table 3. Relationship Between Abnormal Troponin I and Clinical, Radiological, ECG, and
Echocardiography Data
Elevated
Troponin
Normal
Troponin
p
Value
Number of patients 8 31
ST-T changes on ECG 7/8* 11/31 , 0.01
Abnormal echocardiograph 5/8* 0/31 , 0.01
Clinical/radiological evidence of
myocardial dysfunction
4/8* 2/31 , 0.01
Mean ejection fraction (%) 53* 72 0.02
Evidence of cerebral vasospasm 5/8 11/31 0.16
Clinical grade of SAH (grade 3 or .) 6/8* 8/31 , 0.01
Radiological grade of SAH Fisher
scale 4
7/7* 18/30 0.04
Elevated urinary VMA 7/7 19/23 0.23
*Values reach statistical significance.
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tion relate in part to their nonspecificity for the myocardium
and in part to their inability to detect sublethal myocardial
damage (16). The disparity in the incidence of myocardial
injury in SAH reported in our study and those of others
(2,3,30–32) could be attributed to the differing grades of
SAH in the study population, differences in the timing and
methodology of biochemical assays, and the use of cTnI
assay in our study. Only one published study (33) examined
changes in cTnI in SAH and reported an incidence of
myocardial injury of 17%, similar to what was observed in
our trial (20%). However, owing to limited assessment of
myocardial function in that study, other data are not
comparable. The pattern of ECG abnormalities observed in
our study are also consistent with previously published data
(3,4,30,31). The lack of a statistically significant relation-
ship between enzyme changes and development of cerebral
vasospasm in our study is at variance with the data of
Fabinyi et al. (32), who demonstrated clinical or angio-
graphic evidence of cerebral vasospasm in all patients with
elevated cardiac enzymes following a SAH.
Proposed mechanism of myocardial damage. An autopsy
study in humans has suggested that SAH causes vascular
damage to the hypothalamus with subsequent release of
catecholamines, particularly noradrenaline, causing myocar-
dial injury (34). Evidence to support the “catecholamine-
mediated injury” hypothesis also exists in other studies
(35,36), where it has been demonstrated that the histolog-
ical lesions in the myocardium in SAH are similar to
catecholamine-induced damage—that is, contraction band
necrosis and myocytolysis (37,38).
Catecholamine-mediated myocardial injury is probably
multifactorial: tachycardia, coronary spasm and vasocon-
striction, toxic effects on the cardiac myocyte, and increased
intracellular concentration of calcium (39,40). Although
evidence for catecholamine-mediated damage is not sub-
stantiated by urinary VMA data in our study, urinary VMA
is a reflection of serum catecholamines, and the serum
catecholamines do not correlate with tissue catecholamines
(9). These findings are also consistent with the data from
Brouwers et al. (10), who could not demonstrate a relation-
ship between ECG abnormalities in SAH and plasma
noradrenaline concentrations. Myocardial catecholamine
concentrations rise and fall rapidly after an intracranial
catastrophe (41), and these may not be detectable by the
use of urinary VMA. Hypoxia, hypocapnia, and hypoten-
sion were unlikely explanations for the myocardial changes
as all patients were noted to maintain their blood pressure,
arterial oxygen saturation and PCO2 well within the
clinically acceptable range. It is also important to recognize
that the changes in ECG and echocardiography observed
in these patients could be compatible with underlying
coronary artery disease, although a previous study has
demonstrated normal coronary anatomy in this cohort of
patients (6).
The other variable to consider as an underlying etiological
factor in the genesis of myocardial findings is the role of
nimodipine. Nimodipine, a calcium channel blocker, is used
as a cerebral vasodilator (42). Although nimodipine causes
hypotension as a side effect, it has been shown to prevent
ischemic injury in the myocardium (43,44). Maximum
infusion rates of nimodipine were achieved in all our
patients, and no significant episodes of hypotension were
observed. Two of the four patients with clinical or radio-
logical evidence of myocardial dysfunction in the elevated
cTnI group had EFs of 50% or more on echocardiography.
It is likely that in these patients there was a component of
neurogenic pulmonary edema, which has been described in
association with SAH (45).
Clinical implications of the study. The significance of this
study is that it has demonstrated that more severe grades of
SAH are associated with cTnI elevations, and a troponin
leak in this setting is associated with myocardial dysfunc-
tion. This data are also consistent with and extend findings
from previous work that identified both the superiority of
cTnI over CK-MB as a marker of myocardial injury and the
association of troponin leak with adverse outcome in a
variety of conditions, including unstable angina (46), criti-
cally ill patients in intensive care (47), cardiac surgery (20),
and doxorubicin therapy (48). The results from this study
would also strengthen the case for monitoring more closely
those patients with SAH who develop a troponin leak while
in a high dependency unit or an ICU.
Table 4. Relationship Between Abnormal CK and Clinical, Radiological, ECG, and
Echocardiography Data
Elevated
CK-MB/CK-MBI
Normal
CK-MB/CK-MBI p Value
Number of patients 5 34
ST-T changes on ECG 4/5 14/34 0.1
Abnormal echocardiograph 3/5* 2/34 , 0.01
Clinical/radiological evidence of
myocardial dysfunction
2/5 3/34 0.06
Mean ejection fraction (%) 57 70 0.18
Evidence of cerebral vasospasm 5/5* 11/34 , 0.01
Clinical grade of SAH (grade 3 or .) 4/5* 10/34 , 0.05
Radiological grade of SAH Fisher scale 4 5/5 20/32 0.09
Elevated urinary VMA 4/4 22/26 0.39
*Values reach statistical significance.
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Patients with more severe grades of SAH may sometimes
develop intractable intracranial hypertension and become
brain dead. These patients can go on to become organ
donors. Preliminary data from 19 pediatric patients suggest
that elevated donor cTnI is a marker of acute graft failure in
the cardiac recipient (49). Similar data have been published
with regard to cTnT in adult patients (50). In the above
studies, the cutoff values for donor cardiac troponins, above
which there was a strong likelihood of graft failure, were
very high. These data must be treated as preliminary, and a
larger study is required to confirm these data. Nevertheless,
the above studies raise important questions about the
suitability of patients with significant elevations of cTnI
from SAH becoming potential heart donors, and the
combined assessment of cTnI and myocardial function may
provide more useful information.
The presence of myocardial dysfunction raises the ques-
tion of the follow-up studies to determine the duration of
this phenomenon and the presence of any long-term se-
quelae. There is published data in a pediatric population to
show that elevations in cTnI during cytotoxic chemotherapy
predicted delayed ventricular dilatation and thinning (48).
Although this study was not designed to address the
question of long-term damage, this should be the subject of
future studies to determine whether the myocardial dysfunc-
tion is a temporary or a more longer-lasting phenomenon as
this has implications for future management and follow-up.
The presence of a troponin leak raises two anesthetic-
management issues: first, the optimum timing of anesthesia
and surgery and, second, the risk of perioperative cardiovas-
cular deterioration. Recent myocardial injury and congestive
cardiac failure have been consistently identified as risk
factors for perioperative cardiac events in patients presenting
for noncardiac surgery (51). Measures to minimize intraop-
erative cardiac risk could be considered, such as using a
pulmonary artery catheter, avoiding myocardial depressant
agents, and maintaining optimal myocardial oxygen supply
and demand.
Study limitations. One of the limitations of the study was
the exclusion of patients on the basis of preexisting cardiac
disease based on history alone. It is possible that some
patients may have had preexisting subclinical myocardial
ischemia and dysfunction. We performed only one echocar-
diographic examination; serial assessment both during the
acute illness and in the recovery phase may have given
further insight into myocardial dysfunction. The use of
inotropes in certain patients for inotropic and vasopressor
support makes it difficult to interpret urinary catecholamine
and biochemical data.
In conclusion, measurements of serum troponin I reveal a
higher incidence of myocardial injury than predicted by
CK-MB in patients with aneurysmal SAH. When SAH is
accompanied by a raised serum cTnI, it is associated with a
higher incidence of clinical and echocardiographic evidence
of myocardial damage. The cTnI is a highly sensitive and
specific indicator of myocardial dysfunction in aneurysmal
SAH. Similar studies coupled with coronary angiography
and long-term follow-up data are warranted in larger
populations.
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